Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1.]
J.A. Kanis, A. Oden, H. Johansson, F. Borgstrom, O. Strom, E. McCloskey.
FRAX and its applications to clinical practice.
Bone, (2009), 44 pp. 734-743
[2.]
B. Gudbjornsson, U.I. Juliusson, F.V. Gudjonsson.
Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.
Ann Rheum Dis, (2002), 61 pp. 32-36
[3.]
K. Natsui, K. Tanaka, M. Suda, A. Yasoda, Y. Sakuma, A. Ozasa, et al.
High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass.
Osteoporos Int, (2006), 17 pp. 105-108
[4.]
P.L. Selby, J.P. Halsey, K.R. Adams, P. Klimiuk, S.M. Knight, B. Pal, et al.
Corticosteroids do not alter the threshold for vertebral fracture.
J Bone Miner Res, (2000), 15 pp. 952-956
[5.]
K.C. Lian, T.F. Lang, J.H. Keyak, G.W. Modin, Q. Rehman, L. Do, et al.
Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women.
Osteoporos Int, (2005), 16 pp. 642-650
[6.]
A. Angeli, G. Guglielmi, A. Dovio, G. Capelli, D. de Feo, S. Giannini, et al.
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
Bone, (2006), 39 pp. 253-259
[7.]
M. Sosa Henríquez, M. Díaz Curiel, A. Díez Perez, C. Gómez Alonso, J. González Macías, J. Farrerons Minguella, et al.
Guía para la prevención y tratamiento de la osteoporosis inducida por glucocorticoides de la Sociedad Española de Medicina Interna.
Rev Clin Esp, (2008), 208 pp. 33-45
[8.]
J. González Macías, N. Guañabens Gay, C. Gómez Alonso, L. del Rio Barquero, M. Muñoz Torres, M. Delgado, et al.
Guías de práctica clínica en la osteoporosis postmenopáuisca, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral.
Rev Clin Esp, (2008), 28 pp. 1-24
[9.]
T.P. van Staa, H.G. Leufkens, C. Cooper.
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
Osteoporos Int, (2002), 13 pp. 777-787
[10.]
F. De Vries, M. Bracke, H.G. Leufkens, J.W. Lammers, C. Cooper, T.P. Van Staa.
Fracture risk with intermittent high-dose oral glucocorticoid therapy.
Arthritis Rheumatism, (2007), 56 pp. 208-214
[11.]
J.A. Da Silva, J.W. Jacobs, J.R. Kirwan, M. Boers, K.G. Saag, L.B. Inês, et al.
Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.
Ann Rheum Dis, (2006), 65 pp. 285-293
[12.]
Comité de expertos de la SEIOMM.
Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón.
Rev Osteoporos Metab Miner, (2009), 1 pp. 53-60
[13.]
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update.
Arthritis Rheum, (2001), 44 pp. 1496-1503
[14.]
J.N. Hoes, J.W. Jacobs, M. Boers, D. Boumpas, F. Buttgereit, N. Caeyers, et al.
EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
Ann Rheum Dis, (2007), 66 pp. 1560-1567
[15.]
J.P. Devogelaer, S. Goemaere, S. Boonen, J.J. Body, J.M. Kaufman, J.Y. Reginster, et al.
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.
Osteoporos Int, (2006), 17 pp. 8-19
[16.]
Guidelines Working Group for the Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians.
Glucocorticoid induced osteoporosis: guidelines for prevention and treatment.
Royal College of Physicians, (2002),
[17.]
National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Disponible en: www.nof.org
[18.]
J.D. Adachi, K.G. Saag, P.D. Delmas, U.A. Liberman, R.D. Emkey, E. Seeman, et al.
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Arthritis Rheum, (2001), 44 pp. 202-211
[19.]
S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan, et al.
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Calcif Tissue Int, (2000), 67 pp. 277-285
[20.]
C.C. Mok, K.H. Tong, C.H. To, Y.P. Siu, K.M. Ma.
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Osteoporos Int, (2008), 19 pp. 357-364
[21.]
J.D. Ringe, A. Dorst, H. Faber, K. Ibach, F. Sorenson.
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
Osteoporos Int, (2003), 14 pp. 801-807
[22.]
R.N. de Nijs, J.W. Jacobs, W.F. Lems, R.F. Laan, A. Algra, A.M. Huisman, et al.
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
N Engl J Med, (2006), 355 pp. 675-684
[23.]
K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, et al.
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
N Engl J Med, (1998), 339 pp. 292-299
[24.]
S. Cohen, R.M. Levy, M. Keller, E. Boling, R.D. Emkey, M. Greenwald, et al.
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Arthritis Rheum, (1999), 42 pp. 2309-2318
[25.]
D.M. Reid, S. Adami, J.P. Devogelaer, A.A. Chines.
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Calcif Tissue Int, (2001), 69 pp. 242-247
[26.]
D.M. Reid, J.P. Devogelaer, K. Saag, C. Roux, C.S. Lau, J.Y. Reginster, et al.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Lancet, (2009), 373 pp. 1253-1263
[27.]
K.G. Saag, E. Shane, S. Boonen, F. Marín, D.W. Donley, K.A. Taylor, et al.
Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
N Engl J Med, (2007), 357 pp. 2028-2039
[28.]
K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, et al.
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Arthritis Rheum, (2009), 60 pp. 3346-3355
Copyright ©
2010. Elsevier España, S.L.. Todos los derechos reservados
